Featured Press Releases


Seawolf Therapeutics Launches With $100 Million to Advance DNA-Based Therapies

Seawolf Therapeutics announced its emergence from stealth, having raised $100 million to transform patient outcomes through the use of its proprietary DNA delivery platform. Founding investor Versant Ventures led the seed round, followed by the...

Estrella Immunopharma Highlights ARTEMIS® T-Cell Therapy Data at ASH 2026, Demonstrating Promising Leukemia Treatment Results

Estrella Immunopharma, Inc. a clinical-stage biopharmaceutical company developing next-generation ARTEMIS T-cell therapies for cancer and autoimmune diseases, highlighted preclinical findings from an abstract accepted for poster presentation at...

Waters Secures FDA 510(k) Clearance for Leukemia and Lymphoma Flow Cytometry Tests

Waters Corporation announced that the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test have received U.S. Food and Drug Administration (FDA) 510(k) clearance. This clearance enables commercialization in the U.S. and provides pathologists and...

Niagen Bioscience Establishes Skincare as a Permanent Tru Niagen® Category with the Launch of Dermatologist-Tested Niagen NanoCloud™ as a Core Product

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the debut of Tru Niagen® Skincare, a permanent new category in the core Tru Niagen line, led by...

MedaSystems Announces Major Platform Update to Help Life Sciences Organizations Govern and Scale Expanded Access Programs

MedaSystems, a SaaS platform for managing Expanded Access, Post-Trial Access and Investigator-Initiated Study programs, announced the release of MedaSystems Version 3.3, one of the company’s most significant platform updates to date. The release...

CaseBioscience® Joins Team Awarded Up to $7.3 Million by ARPA-H to Advance Ambient Preservation of Cell Therapies

CaseBioscience® announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 million by the Advanced Research Projects Agency for Health (ARPA-H) through its BioStabilization Systems (BoSS) program. Led...

Cronus Pharma Announces the Launch of Florfinasone™ Otic for the Treatment of Otitis Externa in Dogs

Cronus Pharma LLC, a fully integrated animal health company, announced the launch of Florfinasone Otic (florfenicol, terbinafine, mometasone furoate), an FDA-approved product indicated for the treatment of otitis externa in dogs associated with...

Zifo Unveils Vision for an AI-Driven Scientific Semantic Layer in Biopharma

Zifo, a global enabler of AI and data-driven enterprise informatics for science-driven organizations, unveiled its vision for an AI-driven scientific semantic layer, a dynamic framework designed to help Biopharma companies build a more trusted...

Scitara Appoints Mike Tarselli as Chief Strategy Officer to Drive Growth in Lab Intelligence

Scitara, the Lab Connectivity and AI platform company serving the life sciences and biopharma industries, announced a new strategic direction for the company alongside the appointment of Mike Tarselli, Ph.D., MBA, as Chief Strategy Officer. The...

Lundbeck Receives Marketing Authorization for Vyepti® (eptinezumab) in Japan for the Prevention of Migraine Attacks

H. Lundbeck A/S announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has granted marketing authorization for eptinezumab for the prevention of migraine attacks in adults, marking an important milestone for patients in Japan...

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish a Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

AptarGroup, Inc. a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, announced that it has signed an agreement for a research collaboration led by Alice Stanton, PhD from Massachusetts General...

PHC Launched MTR-OPC1-PW Interface Board in September to Strengthen Data Linkage Between Equipment and Customer Systems

PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; Head Office: Chiyoda-ku, Tokyo; President: Shinro Nakamura; hereinafter referred to as "PHC") Life Science Division Biomedica Business Group (PHCbi) is pleased to announce that the MTR-OPC-OPC1-PW,...

Karyopharm Files Supplemental New Drug Application with FDA for XPOVIO® (Selinexor) in Combination with Ruxolitinib for the Treatment of Myelofibrosis

Karyopharm Therapeutics Inc. a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated...

Bruker and Atinary Technologies Join Forces to Accelerate the Future of Self-Driving Laboratories

Bruker Corporation announced an expanded strategic collaboration with Atinary Technologies Inc., the pioneer of Self-Driving Labs® technologies and AI-driven R&D with applications in pharmaceuticals, chemicals, energy, and materials. Bruker also...

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to...

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent...

Excedr Secures $25 Million in Growth Capital to Expand Its Life Sciences Equipment Leasing Platform

Excedr, Inc. a leading provider of full-service laboratory equipment leasing solutions for the life sciences and healthcare industries, announced the closing of $25 million in growth capital. The round includes a $17 million senior credit facility...

China Approves Haisco's Class 1 Innovative Drug, Ciprocopan Succinate Tablets, Providing a New Treatment Option for Patients with PNH

Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the National Medical Products Administration of China...

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs Group Limited a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies, today published a shareholder update from Chief Executive Officer James Foster providing...

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for full approval in children with achondroplasia. . "This...

Results 1 - 20 of 128